Virinchi Limited has formally notified stock exchanges about an upcoming board meeting scheduled to review its quarterly financial performance. The company issued the intimation on January 30, 2026, in accordance with regulatory requirements for listed entities.

Board Meeting Details

The meeting particulars are outlined in the following table:

Financial Results Under Review

The board will consider and approve the unaudited financial statements for two specific periods:

• Third Quarter ended December 31, 2025
• Nine Months ended December 31, 2025

Both standalone and consolidated financial results will be evaluated during the meeting, providing comprehensive insights into the company's performance across different business segments and subsidiaries.

Trading Window Restrictions

Virinchi Limited has implemented mandatory trading restrictions as part of its compliance framework. The trading window will remain closed for the following categories of individuals:

• All Directors
• Promoters
• Designated Employees
• Specified Connected Persons

The restriction period extends until February 06, 2026, ensuring proper adherence to insider trading regulations during the financial results announcement period.

Regulatory Compliance

The intimation was filed under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. Company Secretary K Ravindranath Tagore signed the notification, which was submitted to both BSE Limited and National Stock Exchange of India Limited on January 30, 2026.

Virinchi Limited's board of directors has approved seeking shareholder consent through postal ballot for a significant investment proposal by promoter Mr. Viswanath Kompella in the company's healthcare subsidiary. The board meeting, held on January 20, 2026, addressed the preferential allotment of convertible equity warrants in Virinchi Health Care Private Limited.

Investment Structure and Details

The proposed investment involves the issuance of convertible equity warrants to Mr. Viswanath Kompella, who serves as a promoter of Virinchi Limited. The investment structure has been designed to strengthen the subsidiary's financial position while maintaining strategic control.

Valuation and Regulatory Framework

The warrant pricing is based on a comprehensive enterprise valuation of ₹312.08 crores for Virinchi Health Care Private Limited. This valuation was conducted by Mr. A. Someswara Rao, an IBBI-approved independent registered valuer with registration number IBBI/RV/02/2019/11544.

The investment requires shareholder approval under multiple regulatory provisions:

• Regulation 24 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
• Section 188 of the Companies Act, 2013
• Regulation 30 disclosure requirements

Warrant Conversion Terms

The convertible equity warrants come with specific terms and conditions designed to provide flexibility while ensuring commitment from the investor.

Strategic Rationale

According to the board's assessment, this investment aims to achieve sustainable long-term growth and strengthen ongoing business operations. The infusion of capital is expected to improve liquidity for the company while enhancing the material subsidiary's balance sheet position. The board anticipates that this strategic investment will contribute to enhanced shareholder value creation.

Next Steps and Timeline

The board meeting, which commenced at 7:30 PM and concluded at 8:00 PM on January 20, 2026, formally approved the proposal for postal ballot consideration. The company has indicated that detailed information regarding the postal ballot process, including timelines and procedural requirements, will be communicated to shareholders in due course. The postal ballot will seek formal shareholder approval for the preferential allotment before proceeding with the investment.